Akili Interactive Labs, Inc.
125 Broad Street
About Akili Interactive Labs, Inc.
At Akili, we're in the process of building clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like high-quality video games. Our aim is to develop a new type of Digital Medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians.
Akili was co-founded by PureTech, leading cognitive neuroscientists, and top-tier entertainment software creators. Our operational team is a mix of biomedical scientists and experts in medical device commercialization and interactive design.
CEO: Eddie Martucci, PhD
Chief Creative Officer: Matthew Omernick
27 articles with Akili Interactive Labs, Inc.
PureTech Founded Entity Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Potential Treatment for Patients with COVID Brain Fog
PureTech Health plc is pleased to note that its Founded Entity, Akili Interactive announced collaborations with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to evaluate Akili digital therapeutic AKL-T01 as a treatment for patients with cognitive dysfunction following COVID-19.
Delivered through a video game experience, EndeavorRx has been studied across five clinical studies including a large, randomized controlled trial
The game was reviewed through the agency’s de novo pathway and as a result, creates a new class of digital therapeutics.
Akili Announces FDA Clearance of EndeavorRxTM for Children with ADHD, the First Prescription Treatment Delivered Through a Video Game
Shown to improve attention function, EndeavorRx is backed by data from five clinical studies, including a prospective, randomized controlled trial
Akili Announces ENDEAVORTM Digital Attention Treatment is Now Available for Children with Attention Deficit Hyperactivity Disorder (ADHD) under FDA’s COVID-19 Enforcement Discretion Guidance
Akili announced that ENDEAVORTM is now available for use by children with attention deficit hyperactivity disorder and their families.
Feb. 24, 2020 23:30 UTC Akili Announces Publication of AKL-T01 ADHD Pivotal Study Results in the Lancet Digital Health First publication of complete results shows improvement across both objective measures of attention and parent and clinician ratings of ADHD symptoms and functional impairments Study results suggest AKL-T01 could play an important role in the treatment of pediatric ADHD, directly targeting attention impairments BOSTON--( BUSINESS WIRE )-- Akili In
Akili Study of AKL-T01 With and Without Stimulant Medication in Children With ADHD Achieves Primary Efficacy Endpoint
AKL-T01 showed statistically significant improvement in ADHD Impairment Rating Scale (IRS), when used alone and as adjunct to stimulants
4/12/2019Biopharma companies tap new hires to assume roles in leadership positions, with additions at Metrion, JDRF, Ribometrix, and more.
Santosh Shanbhag joins Akili as Chief Financial Officer Jacqueline Studer joins Akili as Senior Vice President and General Counsel
In addition to the planned BioNTech IPO, many other pharma and biotech companies in Europe, Asia and elsewhere shared news for the week.
PureTech’s Independent Affiliate Akili Announces Partnership with Shionogi to Develop and Commercialise Digital Therapeutics in Certain Asian Markets
Akili receives upfront payments totalling $20 million and has the potential to receive milestone payments for Japan and Taiwan commercialisation of up to an additional $105 million, in addition to substantial royalties on product sales
Akili and Shionogi Announce Strategic Partnership to Develop and Commercialize Digital Therapeutics in Key Asian Markets
Akili to Create First-of-its-kind International Digital Medicine Development and Commercial Platform
Akili Builds Medical Team with Newly Appointed Medical Affairs Leader and Formation of Clinical Advisory Committee in Preparation for Commercial Launch
Anil S. Jina, M.D., Joins Akili to Build and Lead Medical Affairs Team
Recently, BioSpace posted a question on its website, under the heading, “We Want to Hear from You! Top Life Sciences Trends.” Let’s take a look at the five trends survey participants mentioned.
Akili Announces Exclusive Licensing Agreement for New Digital Technology Integrating Neural Systems Targeting and Physical Activity as Novel Cognitive Dysfunction Treatment Platform
Developed by leading neuroscientists at the U.C. San Francisco, currently in multiple clinical trials
Akili Interactive has raised $13 million in new funding as an extension of its Series C financing, which was announced in May.
Andrew Huberman, researcher in the Stanford University Department of Neurobiology, is taking an unusual approach to investigating possible treatments for glaucoma and anxiety disorders—virtual reality.
There are generally two types of antidepressants on the market. They are selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). But there are still individuals who do not respond well to these drugs and the industry continues to work on developing...
5/9/2018Akili Interactive, headquartered in Boston, closed a $55 million Series C financing. Akili is a prescription digital medicine company. Its goal is to treat certain disorders via high-quality video games.
New Patents Issued in U.S. and Japan Broadly Cover Unique Digital Mechanism for Assessing and Improving Cognitive Function